PUNE, India, November 19, 2015 /PRNewswire/ --
New market research titled "EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2024" provides an overview of the risk factors and global trends of AML in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of the following segmentations in adults ages 20 years and older across the 7MM
Complete report on Acute Myeloid Leukemia - Epidemiology Forecast to 2024 spread across 74 pages with 19 tables and 9 figures is now available at http://www.rnrmarketresearch.com/epicast-report-acute-myeloid-leukemia-epidemiology-forecast-to-2024-market-report.html .
Acute myeloid leukemia (AML), also known as myelogenous leukemia, acute myelocytic leukemia, or acute nonlymphocytic leukemia, is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men than in women.
Acute promyelocytic leukemia (APL) and myelodysplastic syndromes (MDS)/therapy-related AML are two subtypes of AML that are especially unique in terms of disease etiology and prognosis, both of which will be discussed in detail in this report. Additionally, AML is associated with molecular gene mutations that are distinct from chromosomal structural abnormalities; of these, the best-studied is the FLT3 mutation (NCI, 2013). AML cases can also be stratified into three prognostic risk groups for treatment planning: favorable, intermediate, and adverse.
Epidemiologists estimate that the 7MM had 40,661 diagnosed incident cases of AML in 2014, nearly half of which occurred in the US. In the next 10 years, the 7MM will experience an increase in disease burden at a rate of 2.03% per year, which will be driven by population increase; this will result in 48,918 diagnosed incident cases of AML in 2024. For 2014, the number of diagnosed prevalent cases of AML was nearly identical to the number of diagnosed incident cases, at 44,079 cases, thereby underlining the lethality and poor long-term survival of the disease. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence. Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=430613 .
Another newly published market research titled Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and key players involved in the therapeutics development for Relapsed Acute Myeloid Leukemia and enlists all their major and minor projects. Relapsed Acute Myeloid Leukemia Pipeline Review research report of 403 pages is available at http://www.rnrmarketresearch.com/relapsed-acute-myeloid-leukemia-pipeline-review-h2-2015-market-report.html .
Explore more reports on Cancer Therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE RnR Market Research